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a b s t r a c t
ONRAB® is a recombinant human adenovirus type 5 (HAd5) with the rabies glycoprotein gene incorporated into its genome. ONRAB® has been used in Canada as an oral rabies vaccine in target wildlife
species such as: red fox (Vulpes vulpes), raccoon (Procyon lotor), and striped skunk (Mepthis mephitis). We
evaluated the safety of ONRAB® in non-target wildlife species likely to contact the vaccine baits during
oral rabies vaccine campaigns in the United States. We investigated the effects of oral inoculation of high
titer ONRAB® , approximately ten times the dose given to target species, in wood rats (Neotoma spp.),
eastern cottontail rabbits (Sylvilagus ﬂoridanus), Virginia opossums (Didelphis virginiana), eastern wild
turkeys (Meleagris gallopavo silvestri), and fox squirrels (Sciurus niger). We performed real-time polymerase chain reaction (PCR) on fecal swabs, oral swabs, and tissues, including lung, liver, kidney, small
intestine, large intestine, and when appropriate nasal turbinates, to detect ONRAB® DNA from inoculated
animals. By seven days post-inoculation, turkeys, opossums, and cottontails had all stopped shedding
ONRAB® DNA. One wood rat and one fox squirrel still had detectable levels of ONRAB® DNA in fecal
swabs 14 days post-inoculation. Real-time PCR analysis of the tissues revealed some ONRAB® DNA persisting in certain tissues; however, there were no signiﬁcant gross or histologic lesions associated with
ONRAB® in any of the species studied. Our results suggest that many non-target species are not likely
to be impacted by the distribution of ONRAB® as part of oral rabies vaccination programs in the United
States.
Published by Elsevier Ltd.

1. Introduction
Rabies viruses in the United States once affected domestic animals and wildlife alike, but since the 1970s have been effectively
eliminated in domestic animals, a result of municipal mandates
requiring pets be vaccinated for rabies. Now control of rabies
virus in the United States focuses on controlling the pathogen in
wildlife reservoirs. Since 1995, the United States National Rabies
Management Program (NRMP), administered by the United States
Department of Agriculture, Animal and Plant Health Inspection
Service, Wildlife Services (WS), has been working to control terrestrial rabies virus through wildlife vaccination. Oral rabies vaccines
are distributed by hand and by ﬁxed and rotary-wing aircraft in
most states east of the Appalachian Mountains, as well as portions
of Ohio, Texas, New Mexico, and Arizona. It is estimated that at least
60% of raccoons (Procyon lotor) in an infected population must be
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immunized against the rabies antigen to eliminate raccoon rabies
[1]. At present, it is estimated that 30% of raccoons are inoculated
[2] by the Oral rabies vaccination (ORV) program in the United
States.
Raboral V-RG® (Merial Ltd., Athens, GA), the vaccine presently
used in the ORV program, is a recombinant vaccine comprised of
a vaccinia virus with the rabies glycoprotein gene inserted into its
genome. Presently, raccoons, gray foxes (Urocyon cinereoargenteus),
coyotes (Canis latrans), and possibly other terrestrial mammals
can be inoculated by ingesting this liquid vaccine, which is contained in a palatable sachet [2,3]. Ideally, when the animal bites
into the sachet the liquid vaccine coats the buccal lining, entering
and replicating in the oral cavity, tonsils, and other surrounding tissues, and stimulates an immune response. However, the
immunogenicity of Raboral V-RG, as determined by measurements
of circulating rabies virus neutralizing antibodies (rVNA), is limited. Brown et al. [4] reported that of 19 wild raccoons inoculated
by Raboral V-RG® 14 succumbed to a rabies challenge. Additionally, a vaccine comparison study in Canada and the United States
found that only 30% of raccoons inoculated in the United States by
Raboral V-RG® demonstrated detectable rVNA ≥0.5 IU/mL, while
nearly 75% of raccoons administered, ONRAB® (Artermis Technologies, Guelph, Ontario, Canada) produced rVNA titers ≥0.5 IU/mL
[5,6].
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ONRAB® is a recombinant oral rabies vaccine with human
adenovirus type 5 (HAd5) as the backbone and the rabies virus glycoprotein gene inserted into its genome. HAd5 is a relatively safe
and well-studied virus, which is used in many vaccine formulations [7–9], but does not replicate well in most non-human species
[10]. The addition of the rabies virus glycoprotein allows the virus
to infect many different species and triggers the host’s immune
system to produce antibodies against the rabies virus [10,11]. Studies on the efﬁcacy and safety of the ONRAB® vaccine in animals
have been completed in Canada [6,11]. Results of ﬁeld and laboratory studies indicated that persistence of the virus in animals is
short-lived and that ONRAB® is unlikely to have an overall negative
impact on wildlife [6,10–12]. Rabies virus seroconversion rates for
raccoons in areas baited with ONRAB® averaged 80% in the ﬁrst two
years [13], well above the seroconversion rates detected when the
vaccine Raboral V-RG® was used [3,4].
Knowles et al. conducted vaccine safety and immunogenicity studies on 18 species: striped skunks, red foxes (V. vulpes),
raccoons, meadow voles (Microtus pennsylvanicus), deer mice (Peromyscus leucopus), gray squirrels (Sciurus carolinensis), laboratory
rabbits (Oryctologu cuniculus), ground squirrels (Marmota monax),
cattle (Bos taurus), horses (Equus ferus), domestic swine (Sus domesticus), domestic chickens (Gallus domesticus), sheep (Ovis aries),
dogs (Canis familiaris), cats (Felis domesticus), cotton rats (Sigmodon hispidus), SCID mice and nude mice (Mus musculus) [11].
For their non-target safety trials, Knowles et al. [11] administered
an ONRAB® dose approximately 10 times greater than that needed
to vaccinate target species. Animals were monitored daily and all
tolerated exposure to the vaccine. Analyses of tissues resulted in
viral DNA detected in some lung and kidney samples. Following
histopathological analysis, the most marked ﬁndings were in the
lungs with pulmonary congestion possibly due to vaccine aspiration. Oral swabs and/or fecal samples were collected from skunks,
raccoons, foxes, cotton rats, cats and dogs. Viral shedding, if any,
was generally complete by 4 days post-inoculation (dpi) except for
one skunk, which continued to shed virus in feces through 14 dpi
[11].
Our research expands on the species evaluated by Knowles et al.
[11] and investigates the vaccine as it relates to its safety in wildlife
species likely to come in contact with ONRAB® as part of WS NRMP
ORV operations. We investigated the effects of oral inoculation of
high titer ONRAB® vaccine in 21 eastern wild turkeys (Meleagris
gallopavo silvestri), 17 opossums (Didelphis virginiana), 14 cottontail
rabbits (Sylvilagus ﬂoridanus), 21 fox squirrels (Sciurus niger), and
15 wood rats (Neotoma spp.). We preformed post-mortem examination to determine any gross or histological pathology that may
be linked to the vaccine. We assessed immunogenicity of ONRAB®
in the non-target animals and evaluated the duration of viral DNA
shed into the environment via fecal and oral shedding. We also
investigated the persistence of ONRAB DNA in select tissues of vaccinated animals.

2.2. Vaccination
Artemis Technologies Inc. (Guelph, Ontario, Canada) supplied
us with bulk ONRAB® oral rabies vaccine under the United States
Veterinary Biological Product Permit No. VB-118764. The 50%
cell culture infectious dose (CCID50 ) of the vaccine was 1010.44
CCID50 /mL. We followed the methods described by Knowles [11]
et al. and orally inoculated animals with 1.8 mL dose of vaccine,
which resulted in an infectious virus titer approximately 10 times
higher than found in a standard ONRAB® bait.
2.3. Sample collection
We evaluated the safety of the ONRAB® vaccine via numerous
tests and observations following the methods of Knowles et al. [11].
On a daily basis we monitored animals for changes in behavior and
eating habits. We looked for shedding of ONRAB® DNA via oral
swabs on 0, 4, and 7 days post infection (dpi) in turkeys, cottontail rabbits, opossums and fox squirrels and on 0 and 4 dpi in wood
rats. We also collected feces on 0–7, 14, 21, and 28 dpi for all species.
We collected paired blood samples on 0 and 28 dpi to evaluate sera
for Rabies virus neutralizing antibodies (rVNA).
One-half of the study animals for each species were humanly
euthanized on 4 dpi, when viral replication should be at or near
its peak [11–12,14]. The remaining individuals were euthanized
at the conclusion of the study (28 dpi). Turkeys were euthanized by an intravenous injection of an overdose of barbiturates.
Opossums were anesthetized with 10 mg/kg ketamine HCl and
2 mg/kg xylazine via intramuscular injection before receiving an
intracardiac injection of an overdose of barbiturates. Cottontail
rabbits and fox squirrels were anesthetized with isoﬂurane then
given an overdose of barbiturates via intracardiac injection. Wood
rats were euthanized by an inhaled overdose of isoﬂurane.
2.4. Post-mortem examination
Following euthanasia on either 4 dpi or 28 dpi, a standard postmortem examination was conducted by a veterinary pathologist.
Any abnormal tissue and routine sections of lung, liver, kidney,
small intestine, and large intestine were preserved in 10% neutral
buffered formalin for histology. Tissues were embedded in parafﬁn,
cut at 5 m, stained with hematoxylin and eosin stain and examined histologically. Fresh tissues were also collected for ONRAB®
DNA detection by real-time PCR.
2.5. Serological methods
Serum samples were heat inactivated at 56 ◦ C for 30 min. Rabies
virus neutralizing antibodies were detected in the sera by use of the
rapid ﬂuorescent focus inhibition test (RFFIT), as described by Smith
et al. [15]. Murine neuroblastoma cells were used for infection by
the CVS rabies virus strain. Sera with rVNA activity ≥0.2 IU/ml were
considered positive samples.

2. Materials and methods
2.6. Real-time polymerase chain reaction
2.1. Study animals
All animals were wild caught with the exception of the eastern
wild turkeys which were purchased from a commercial breeder
(McMurry Hatchery, Webster City, IA, USA) and shipped at 2 days
old. All animal trapping, handling, maintenance, and sampling techniques were approved by the WS National Wildlife Research Center
(NWRC) Institutional Animal Care and Use Committee (QA1882).
Animals were trapped and transported under permits issued by
the State of Colorado (Permit #11TR1232A1, Permit # 12TR1232)
and individually housed throughout the study.

We used the MagMAXTM Viral RNA isolation kit (Life Technologies, Grand Island, NY, USA), which is also recommended for
isolating DNA, to extract ONRAB® DNA from fecal and oral swabs.
The DNeasy Blood & Tissue kit (Qiagen, Valencia, California, USA)
was used to isolate DNA from 10 to 25 mg of lung, liver, kidney,
small intestine, large intestine, and nasal turbinates as directed by
the manufacturer. Real-time PCR was performed on the extracted
DNA using published primers and a dual-labeled probe for an
ONRAB target sequence [11]. Twenty-ﬁve milliliter PCR reactions
containing 1× TaqMan Universal Master mix (Life Technologies,
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Table 1
The frequency of oral and fecal samples positive for ONRAB® DNA by real-time PCR, by species, following vaccination with ONRAB® .
Positive fecal swabs (na )

Positive oral swabs (n)

dpi

1

2

3

4

5

6

7

14

4

7

Eastern wild turkey
Opossum
Eastern cottontail
Fox squirrel
Wood rat

14 (21)
9 (17)
4 (13)
17 (21)
1 (15)

6 (21)
17 (17)
0 (14)
16 (21)
2 (15)

1 (21)
12 (14)
2 (14)
17 (20)
1 (15)

0 (21)
5 (17)
0 (14)
12 (21)
9 (15)

0 (10)
5 (17)
1 (7)
8 (11)
–

0 (10)
2 (8)
0 (7)
9 (11)
–

0 (10)
0 (8)
0 (7)
8 (11)
1 (7)

0 (10)
0 (8)
0 (7)
1 (11)
1 (7)

1 (21)
3 (17)
1 (14)
19 (21)
0 (15)

0 (10)
0 (8)
0 (7)
3 (11)
–

a

Sample size includes number of inoculated individuals tested.

Table 2
The frequency of tissue samples positive for ONRAB® DNA by real-time PCR, by species, following vaccination with ONRAB® .
dpi
Eastern wild turkey
Opossum
Eastern cottontail
Fox squirrel
Wood rat

4
28
4
28
4
28
4
28
4
28

Lung (n)
2 (11)
0 (10)
0 (9)
0 (8)
4 (7)
2 (7)
9 (10)
4 (11)
0 (8)
0 (7)

Liver (n)
0 (11)
0 (10)
0 (9)
1 (8)
0 (7)
0 (7)
6 (10)
1 (11)
3 (9)
1 (7)

Kidney (n)
0 (11)
0 (10)
0 (9)
1 (8)
0 (7)
0 (7)
8 (10)
1 (11)
0 (9)
0 (7)

Grand Island, New York, USA), 400 nM forward primer, 400 nM
reverse primer, 400 nM dual-labeled probe, and 3 l DNA template were analyzed with an ABI 7900HT real-time PCR system (Life
Technologies, Grand Island, New York) under the following conditions: 50 ◦ C for 2 min, 95 ◦ C for 10 min and then 45 cycles of 95 ◦ C
for 10 s and 60 ◦ C for 1 min. The working range of the assay was
approximately 103 –108 TCID50 /mL PCR equivalents [9] and samples with cycle threshold (Ct) values less than 37 (approximately
103 TCID50 /mL or greater) were considered positive for ONRAB®
DNA.
3. Results and discussion
We did not observe any behavior changes in any of the animals
inoculated with ONRAB® . All gross and histologic lesions seen in all
species were interpreted as secondary to natural infection or experimental protocol. Numerous parasites were considered incidental
ﬁndings in inoculates. Pneumonia and lymphoid hyperplasia seen
in the lungs of a single wood rat were interpreted as secondary to
aspiration and antigenic stimulation.
We did not detect rVNA in any day 0 samples, regardless of
species (<0.06 IU/ml). We used the RFFIT to determine that the
majority of animals (91%) responded with the induction of rVNA
from comparison of paired sera samples, sera collected at 0 and
28 dpi from the same individual. Eight of 10 inoculated turkeys
had evidence of rVNA, and all positive samples were >0.2 IU/ml. In
inoculated opossums, 8 of 8 had evidence of rVNA, and all positive
samples were >0.2 IU/ml. For the inoculated cottontail rabbits, 6 of 7
day had evidence of rVNA, and all positive samples were >0.2 IU/ml.
Eleven of 11 inoculated fox squirrels had evidence of rVNA, and
all positive samples were >17 IU/ml. Six of 8 inoculated woodrats
had evidence of rVNA, and all positive samples were >2.7 IU/ml.
These results show that nearly all animals, 91%, developed a positive rabies antibody response after being orally inoculated with
ONRAB® .
By 7 dpi no ONRAB® DNA was detected in the fecal swabs of
turkeys, opossums, or cottontails (Table 1). One wood rat and
eight fox squirrels still had detectable levels of ONRAB® DNA in
fecal swabs on 7 dpi. The high number of fox squirrels still shedding ONRAB® DNA at 7 dpi was unexpected and may be explained
by more efﬁcient viral replication in fox squirrel cells or some
false-positive detection by PCR. Additionally, at necropsy it was

Small intestine (n)

Large intestine (n)

Nasal turbinates (n)

0 (11)
0 (10)
0 (9)
0 (8)
1 (7)
0 (7)
3 (10)
0 (11)
0 (9)
0 (7)

–
4 (11)
0 (10)
0 (9)
0 (8)
2 (7)
1 (7)
5 (10)
0 (11)
0 (9)
0 (7)

0 (9)
1 (8)
0 (7)
1 (7)
0 (10)
1(11)
0 (9)
0 (7)

determined that at least 50% of fox squirrels were co-infected with
Leptospira interrogans [16]. This co-infection may be a confounding factor, compromising an animal’s immune system and ability
to clear the virus, resulting in the prolonged detection of ONRAB®
DNA in fecal swabs from these animals. At 14 dpi, we recovered
ONRAB® DNA from fecal swabs of one wood rat and a single fox
squirrel; by 21 dpi no ONRAB® DNA from fecal swabs was detected
in any individuals.
Oral shedding of ONRAB® DNA on 4 dpi was only detected in
3 opossums, and one turkey and one cottontail, but nearly all fox
squirrels (Table 1). At 7 dpi, only three fox squirrels exhibited oral
shedding. With the exception of our fox squirrels, we considered
the potential persistence of ONRAB® in many non-target species
to be low given the limited ONRAB DNA recovery through both
oral and fecal sampling. Because we only tested for the presence of
ONRAB DNA, we cannot assess whether or not infectious virus was
being shed.
Although no pathology was noted, we detected ONRAB® DNA
in all tissue types sampled (Table 2). ONRAB® DNA was detected
most often in lung tissue, followed by liver and large intestine, kidney, small intestine, and nasal turbinates. There appeared to be
some species variation as ONRAB® DNA was isolated in tissues of
14 fox squirrels, six cottontails, four turkeys, four wood rats, and
only one opossum. Although varied, our results likely show individual variation as opposed to widespread shedding and persistence
of ONRAB® .
Our results were not unexpected, and we concur with previous research [6,11,12] suggesting a low likelihood of persistence
of ONRAB® in the environment or in individual animals that contact the vaccine even at ten times the recommended dose. To date
there have been no known negative impacts on target or non-target
animals following large-scale distributions of ONRAB in Canada
[12]. Based on the results of our study, ONRAB® is not expected to
have detrimental effects on non-target wildlife species if incidental
ingestion occurs following ORV campaigns in the United States.
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